Vertebral artery dissection presenting as a Brown-Séquard syndrome: a case report

<p>Abstract</p> <p>Introduction</p> <p>Vertebral artery dissection has become increasingly recognized as an important cause of stroke. It usually presents with posterior headache or neck pain followed within hours or days by signs of posterior circulation stroke. To the best of our knowledge, the clinical presentation of a Brown-Séquard syndrome with a vertebral artery dissection has been reported only once before.</p> <p>Case presentation</p> <p>An otherwise healthy 35-year-old man presented with acute left-sided weakness. He had experienced left-sided posterior neck pain after a 4-hour flight 4 weeks previously. Physical examination was consistent with a left Brown-Séquard syndrome. Magnetic resonance angiography showed evidence of left vertebral artery dissection. He improved after therapy with anticoagulants.</p> <p>Conclusion</p> <p>We report a case of an unusual presentation of a relatively uncommon condition. This diagnosis should be considered early in relatively young patients with stroke-like symptoms or unexplained neck pain, because missing a dissection can result in adverse outcomes.</p

Congenital dislocation of the hip: Optimal screening strategies in 2014

AbstractA prospective multi-centre nationwide study of patients with congenital dislocation of the hip (CDH) diagnosed after 3 months of age was conducted with support from the French Society for Paediatric Orthopaedics (Société Française d’Orthopédie Pédiatrique [SoFOP]), French Organisation for Outpatient Paediatrics (Association Française de Pédiatrie Ambulatoire [AFPA]), and French-Speaking Society for Paediatric and Pre-Natal Imaging (Société Francophone d’Imagerie Pédiatrique et Prénatale [SFIPP]). The results showed inadequacies in clinical screening for CDH that were patent when assessed quantitatively and probably also present qualitatively. These findings indicate a need for a communication and educational campaign aimed at highlighting good clinical practice guidelines in the field of CDH screening. The usefulness of routine ultrasound screening has not been established. The findings from this study have been used by the authors and French National Health Authority (Haute Autorité de Santé [HAS]) to develop recommendations about CDH screening. There is an urgent need for a prospective randomised multi-centre nationwide study, which should involve primary-care physicians

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist

OBJECTIVE Improvement in treatment outcome for patients with glioblastoma multiforme (GBM) requires a multifaceted approach due to dysregulation of numerous signaling pathways. The murine double minute 2 (MDM2) protein may fulfill this requirement because it is involved in the regulation of growth, survival, and invasion. The objective of this study was to investigate the impact of modulating MDM2 function in combination with front-line temozolomide (TMZ) therapy in GBM. METHODS The combination of TMZ with the MDM2 protein-protein interaction inhibitor nutlin3a was evaluated for effects on cell growth, p53 pathway activation, expression of DNA repair proteins, and invasive properties. In vivo efficacy was assessed in xenograft models of human GBM. RESULTS In combination, TMZ/nutlin3a was additive to synergistic in decreasing growth of wild-type p53 GBM cells. Pharmacodynamic studies demonstrated that inhibition of cell growth following exposure to TMZ/nutlin3a correlated with: 1) activation of the p53 pathway, 2) downregulation of DNA repair proteins, 3) persistence of DNA damage, and 4) decreased invasion. Pharmacokinetic studies indicated that nutlin3a was detected in human intracranial tumor xenografts. To assess therapeutic potential, efficacy studies were conducted in a xenograft model of intracranial GBM by using GBM cells derived from a recurrent wild-type p53 GBM that is highly TMZ resistant (GBM10). Three 5-day cycles of TMZ/nutlin3a resulted in a significant increase in the survival of mice with GBM10 intracranial tumors compared with single-agent therapy. CONCLUSIONS Modulation of MDM2/p53-associated signaling pathways is a novel approach for decreasing TMZ resistance in GBM. To the authors' knowledge, this is the first study in a humanized intracranial patient-derived xenograft model to demonstrate the efficacy of combining front-line TMZ therapy and an inhibitor of MDM2 protein-protein interactions

Multiple drug resistant tuberculosis in patients addicted to alcohol – a critical issue of the current tuberculosis control

The article presents the comparative description of multiple resistant tuberculosis patients (MDR TB) abusing alcohol (group 1 – 169 people), and not abusing alcohol (group 2 – 122 persons); the frequency and specificity of adverse reaction to anti-tuberculosis drugs, immediate and postponed treatment outcomes have been studied. The negative effect of the alcohol abuse on the majority of the studied rates has been found out. Disseminated forms, fibrous cavernous tuberculosis, intoxication syndrome, chronic respiratory, intestinal and liver diseases, as well as incarceration experience are observed more often among alcohol dependent MDR TB patients. It is confidently true that adverse reactions occur more often (84.6% versus 57.6%), including toxic reactions, they are more severe and intractable, especially hepato- and neuro-toxic ones.Efficiency of in-patient treatment is confidently lower in the 1st group – 61.7% versus 82.8%. The cessation of bacillary excretion was lower (69.7% versus 85.6%). The hospital mortality was also higher in the 1st group (8.6% versus 0.9%).The postponed results of 2 – 6 year follow up are worse in the patients abusing alcohol. The successful treatment outcomes with criteria of cured, treatment completed were observed in the 60.4% in the 1st group of patient, while in the 2nd group this rate made 80.8% (p &lt; 0.05), the mortality and disability rates were also higher as well as the number of patients in whom bacillary excretion persisted (38.3% versus 19.2%, p &lt; 0.05).70% of patients demonstrated favorable treatment outcomes